MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brexpiprazole.
Abiraterone
The serum concentration of Brexpiprazole can be increased when it is combined with Abiraterone.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Brexpiprazole.
Acebutolol
Acebutolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Acepromazine
Acepromazine may increase the antihypertensive activities of Brexpiprazole.
Aceprometazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Aceprometazine.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Brexpiprazole.
Acetyl Sulfisoxazole
The serum concentration of Brexpiprazole can be increased when it is combined with Acetyl sulfisoxazole.
Adrafinil
Brexpiprazole may decrease the vasoconstricting activities of Adrafinil.
Albuterol
Brexpiprazole may decrease the vasoconstricting activities of Salbutamol.
Alfaxalone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Brexpiprazole.
Alfuzosin
Alfuzosin may increase the antihypertensive activities of Brexpiprazole.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Brexpiprazole.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Brexpiprazole.
Alphaprodine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Brexpiprazole.
Alprenolol
Alprenolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Amiodarone
The serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.
Amisulpride
Brexpiprazole may increase the antipsychotic activities of Amisulpride.
Amitriptyline
Amitriptyline may increase the antihypertensive activities of Brexpiprazole.
Amlodipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Amlodipine.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Brexpiprazole.
Amoxapine
Amoxapine may increase the antihypertensive activities of Brexpiprazole.
Amphetamine
The metabolism of Brexpiprazole can be decreased when combined with Amphetamine.
Apalutamide
The serum concentration of Brexpiprazole can be decreased when it is combined with Apalutamide.
Apomorphine
Brexpiprazole may decrease the vasoconstricting activities of Apomorphine.
Apraclonidine
Brexpiprazole may decrease the vasoconstricting activities of Apraclonidine.
Aprepitant
The serum concentration of Brexpiprazole can be increased when it is combined with Aprepitant.
Arbutamine
Brexpiprazole may decrease the vasoconstricting activities of Arbutamine.
Arformoterol
Brexpiprazole may decrease the vasoconstricting activities of Arformoterol.
Aripiprazole
Aripiprazole may increase the antihypertensive activities of Brexpiprazole.
Artemether
The serum concentration of Brexpiprazole can be increased when it is combined with Artemether.
Articaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Articaine.
Asenapine
Asenapine may increase the antihypertensive activities of Brexpiprazole.
Atazanavir
The serum concentration of Brexpiprazole can be increased when it is combined with Atazanavir.
Atenolol
Atenolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Atomoxetine
The serum concentration of Brexpiprazole can be increased when it is combined with Atomoxetine.
Avanafil
Avanafil may increase the hypotensive activities of Brexpiprazole.
Azelastine
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Brexpiprazole.
Bambuterol
Brexpiprazole may decrease the vasoconstricting activities of Bambuterol.
Barbital
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Barbital.
Bencyclane
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Bencyclane.
Benoxinate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Benzocaine.
Benzphetamine
Brexpiprazole may decrease the stimulatory activities of Benzphetamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Benzyl alcohol.
Bepridil
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Bepridil.
Betaxolol
The serum concentration of Brexpiprazole can be increased when it is combined with Betaxolol.
Bioallethrin
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Bioallethrin.
Bisoprolol
Bisoprolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Bitolterol
Brexpiprazole may decrease the vasoconstricting activities of Bitolterol.
Bitolterol Mesylate
Brexpiprazole may decrease the vasoconstricting activities of Bitolterol.
Boceprevir
The serum concentration of Brexpiprazole can be increased when it is combined with Boceprevir.
Bopindolol
Bopindolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Bortezomib
The serum concentration of Brexpiprazole can be increased when it is combined with Bortezomib.
Bosentan
The serum concentration of Brexpiprazole can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Brexpiprazole can be decreased when it is combined with Bosentan.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Brexpiprazole.
Bromocriptine
Bromocriptine may increase the vasoconstricting activities of Brexpiprazole.
Bromperidol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Brexpiprazole.
Brotizolam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Brotizolam.
Bunazosin
Bunazosin may increase the antihypertensive activities of Brexpiprazole.
Bupivacaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Bupivacaine.
Bupranolol
Bupranolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Buprenorphine
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The serum concentration of Brexpiprazole can be increased when it is combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Brexpiprazole.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Brexpiprazole.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Brexpiprazole.
Butamben
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Brexpiprazole.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Brexpiprazole.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
Carbamazepine
The serum concentration of Brexpiprazole can be decreased when it is combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brexpiprazole.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Brexpiprazole.
Carteolol
Carteolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Carvedilol
Carvedilol may increase the antihypertensive activities of Brexpiprazole.
Celecoxib
The serum concentration of Brexpiprazole can be increased when it is combined with Celecoxib.
Celiprolol
Celiprolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Ceritinib
The serum concentration of Brexpiprazole can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Brexpiprazole.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brexpiprazole.
Chlormethiazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chloroprocaine.
Chloroquine
The serum concentration of Brexpiprazole can be increased when it is combined with Chloroquine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Brexpiprazole.
Chlorpromazine
The serum concentration of Brexpiprazole can be increased when it is combined with Chlorpromazine.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Brexpiprazole.
Chlorprothixene
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brexpiprazole.
Cholecalciferol
The serum concentration of Brexpiprazole can be increased when it is combined with Cholecalciferol.
Cimetidine
The serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.
Cinacalcet
The serum concentration of Brexpiprazole can be increased when it is combined with Cinacalcet.
Cinnarizine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Cinnarizine.
Citalopram
The serum concentration of Brexpiprazole can be increased when it is combined with Citalopram.
Clarithromycin
The serum concentration of Brexpiprazole can be increased when it is combined with Clarithromycin.
Clemastine
The serum concentration of Brexpiprazole can be increased when it is combined with Clemastine.
Clenbuterol
Brexpiprazole may decrease the vasoconstricting activities of Clenbuterol.
Clevidipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Clevidipine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Brexpiprazole.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Brexpiprazole.
Clobazam
The serum concentration of Brexpiprazole can be increased when it is combined with Clobazam.
Clomipramine
The serum concentration of Brexpiprazole can be increased when it is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Brexpiprazole.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Brexpiprazole.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.
Clotrimazole
The serum concentration of Brexpiprazole can be increased when it is combined with Clotrimazole.
Clozapine
The serum concentration of Brexpiprazole can be increased when it is combined with Clozapine.
Cobicistat
The serum concentration of Brexpiprazole can be increased when it is combined with Cobicistat.
Cocaine
The serum concentration of Brexpiprazole can be increased when it is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Brexpiprazole.
Crizotinib
The serum concentration of Brexpiprazole can be increased when it is combined with Crizotinib.
Curcumin
The serum concentration of Brexpiprazole can be increased when it is combined with Curcumin.
Cyclandelate
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Cyclandelate.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Brexpiprazole.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.
Cyclosporine
The serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brexpiprazole.
Dabrafenib
The serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.
Dapiprazole
Dapiprazole may increase the antihypertensive activities of Brexpiprazole.
Darifenacin
The serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin.
Darunavir
The serum concentration of Brexpiprazole can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Brexpiprazole can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Brexpiprazole can be increased when it is combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Brexpiprazole.
Desipramine
The serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Brexpiprazole.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Brexpiprazole.
Deutetrabenazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dexmedetomidine.
Dextroamphetamine
Dextroamphetamine may increase the antihypertensive activities of Brexpiprazole.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Brexpiprazole.
Dextromoramide
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Brexpiprazole.
Dibucaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Cinchocaine.
Diethylpropion
Brexpiprazole may decrease the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Brexpiprazole.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brexpiprazole.
Dihydroergotamine
The serum concentration of Brexpiprazole can be increased when it is combined with Dihydroergotamine.
Diltiazem
The serum concentration of Brexpiprazole can be increased when it is combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brexpiprazole.
Diphenhydramine
The serum concentration of Brexpiprazole can be increased when it is combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brexpiprazole.
Dipivefrin
Brexpiprazole may decrease the vasoconstricting activities of Dipivefrin.
Dipyridamole
Dipyridamole may increase the hypotensive activities of Brexpiprazole.
Dobutamine
Brexpiprazole may decrease the vasoconstricting activities of Dobutamine.
Dopexamine
Brexpiprazole may decrease the vasoconstricting activities of Dopexamine.
Dothiepin
The serum concentration of Brexpiprazole can be increased when it is combined with Dosulepin.
Doxazosin
Doxazosin may increase the antihypertensive activities of Brexpiprazole.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Brexpiprazole.
Doxycycline
The serum concentration of Brexpiprazole can be increased when it is combined with Doxycycline.
Doxycycline Anhydrous
The serum concentration of Brexpiprazole can be increased when it is combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Dronedarone
The serum concentration of Brexpiprazole can be increased when it is combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Droxidopa
Brexpiprazole may increase the hypertensive activities of Droxidopa.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Brexpiprazole.
Duloxetine
The serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dyclonine.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Brexpiprazole.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Brexpiprazole.
Eliglustat
The serum concentration of Brexpiprazole can be increased when it is combined with Eliglustat.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.
Enflurane
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Brexpiprazole.
Enzalutamide
The serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide.
Ephedrine
Brexpiprazole may decrease the vasoconstricting activities of Ephedrine.
Epinastine
Brexpiprazole may decrease the vasoconstricting activities of Epinastine.
Epinephrine
Brexpiprazole may increase the antihypertensive activities of Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.
Ergonovine
Ergonovine may increase the vasoconstricting activities of Brexpiprazole.
Ergotamine
Ergotamine may increase the vasoconstricting activities of Brexpiprazole.
Erythromycin
The serum concentration of Brexpiprazole can be increased when it is combined with Erythromycin.
Escitalopram
Escitalopram may increase the antihypertensive activities of Brexpiprazole.
Esmolol
Esmolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Brexpiprazole.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Brexpiprazole.
Ethanol
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Brexpiprazole.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Brexpiprazole.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etifoxine.
Etilefrine
Brexpiprazole may decrease the vasoconstricting activities of Etilefrine.
Etomidate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etomidate.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Brexpiprazole.
Ezogabine
The risk or severity of adverse effects can be increased when Ezogabine is combined with Brexpiprazole.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Brexpiprazole.
Felodipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Felodipine.
Fendiline
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Fendiline.
Fenoterol
Brexpiprazole may decrease the vasoconstricting activities of Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Brexpiprazole.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Brexpiprazole.
Fish Oils
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Fish oil.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Brexpiprazole.
Fluconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Fluconazole.
Flunarizine
The risk or severity of adverse effects can be increased when Flunarizine is combined with Brexpiprazole.
Flunitrazepam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Flunitrazepam.
Fluoxetine
The serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Brexpiprazole.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Brexpiprazole.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Brexpiprazole.
Fluspirilene
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brexpiprazole.
Fluvoxamine
The serum concentration of Brexpiprazole can be increased when it is combined with Fluvoxamine.
Formoterol
Brexpiprazole may decrease the vasoconstricting activities of Formoterol.
Fosamprenavir
The serum concentration of Brexpiprazole can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Brexpiprazole can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Brexpiprazole can be decreased when it is combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fospropofol.
Fostamatinib
Fostamatinib may increase the hypotensive activities of Brexpiprazole.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Brexpiprazole.
Furazolidone
The metabolism of Brexpiprazole can be decreased when combined with Furazolidone.
Fusidate
The serum concentration of Brexpiprazole can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Brexpiprazole can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Brexpiprazole.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Brexpiprazole.
Gallopamil
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Gallopamil.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Brexpiprazole.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Brexpiprazole.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Brexpiprazole.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Brexpiprazole.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Brexpiprazole.
Glutethimide
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Glutethimide.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Brexpiprazole.
Guanabenz
Brexpiprazole may decrease the vasoconstricting activities of Guanabenz.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Brexpiprazole.
Halazepam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Halazepam.
Haloperidol
The serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Hexobarbital.
Hexoprenaline
Brexpiprazole may decrease the vasoconstricting activities of Hexoprenaline.
Hydrocodone
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Hypoxis hemerocallidea root extract
The serum concentration of Brexpiprazole can be decreased when it is combined with St. John's Wort.
Idelalisib
The serum concentration of Brexpiprazole can be increased when it is combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Brexpiprazole.
Imatinib
The serum concentration of Brexpiprazole can be increased when it is combined with Imatinib.
Imipramine
The serum concentration of Brexpiprazole can be increased when it is combined with Imipramine.
Inamrinone
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Amrinone.
Indacaterol
Brexpiprazole may decrease the vasoconstricting activities of Indacaterol.
Indinavir
The serum concentration of Brexpiprazole can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Brexpiprazole can be increased when it is combined with Indinavir.
Indoramin
Indoramin may increase the antihypertensive activities of Brexpiprazole.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Brexpiprazole.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Brexpiprazole.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Brexpiprazole.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Brexpiprazole.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Brexpiprazole.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Brexpiprazole.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Brexpiprazole.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Brexpiprazole.
Iproniazid
The metabolism of Brexpiprazole can be decreased when combined with Iproniazid.
Isavuconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Isavuconazole.
Isavuconazonium
The serum concentration of Brexpiprazole can be increased when it is combined with Isavuconazonium.
Isocarboxazid
The metabolism of Brexpiprazole can be decreased when combined with Isocarboxazid.
Isoetharine
Brexpiprazole may decrease the vasoconstricting activities of Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Brexpiprazole.
Isometheptene
Brexpiprazole may decrease the vasoconstricting activities of Isometheptene.
Isoniazid
The serum concentration of Brexpiprazole can be increased when it is combined with Isoniazid.
Isoproterenol
Brexpiprazole may decrease the vasoconstricting activities of Isoprenaline.
Isoxsuprine
Brexpiprazole may decrease the vasoconstricting activities of Isoxsuprine.
Isradipine
The serum concentration of Brexpiprazole can be increased when it is combined with Isradipine.
Itraconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Brexpiprazole can be increased when it is combined with Ivacaftor.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Brexpiprazole.
Ketazolam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ketazolam.
Ketoconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Ketoconazole.
Labetalol
Labetalol may increase the antihypertensive activities of Brexpiprazole.
Lacidipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Lacidipine.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Brexpiprazole.
Lercanidipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Lercanidipine.
Levalbuterol
Brexpiprazole may decrease the vasoconstricting activities of Levosalbutamol.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Brexpiprazole.
Levobetaxolol
Levobetaxolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Levobupivacaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Brexpiprazole.
Levodopa
The risk or severity of adverse effects can be increased when Levodopa is combined with Brexpiprazole.
LEVOMENTHOL
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Menthol.
Levomethadyl
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Brexpiprazole.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Brexpiprazole.
Lidocaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Lidocaine.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Brexpiprazole.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Brexpiprazole.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Brexpiprazole.
Lisdexamfetamine
Lisdexamfetamine may increase the antihypertensive activities of Brexpiprazole.
Lisdexamfetamine Dimesylate
Brexpiprazole may decrease the stimulatory activities of Lisdexamfetamine.
Lithium
Lithium may increase the neurotoxic activities of Brexpiprazole.
Lithium Cation
Lithium may increase the neurotoxic activities of Brexpiprazole.
Lofexidine
The therapeutic efficacy of Brexpiprazole can be increased when used in combination with Lofexidine.
Loperamide
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Loperamide.
Lopinavir
The serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Brexpiprazole.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Brexpiprazole.
Lorcaserin
The serum concentration of Brexpiprazole can be increased when it is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Lormetazepam.
Lovastatin
The serum concentration of Brexpiprazole can be increased when it is combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Brexpiprazole.
Luliconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Brexpiprazole can be decreased when it is combined with Lumacaftor.
Lumefantrine
The serum concentration of Brexpiprazole can be increased when it is combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.
Magnesium Sulfate
The therapeutic efficacy of Brexpiprazole can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Brexpiprazole can be increased when used in combination with Magnesium sulfate.
Manidipine
The serum concentration of Brexpiprazole can be increased when it is combined with Manidipine.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Brexpiprazole.
Melatonin
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Melatonin.
Menthol
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Menthol.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Brexpiprazole.
Mephentermine
Brexpiprazole may decrease the stimulatory activities of Mephentermine.
Mephobarbital
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenobarbital.
Mepindolol
Mepindolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Mepirodipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Barnidipine.
Mepivacaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.
Mequitazine
Brexpiprazole may increase the arrhythmogenic activities of Mequitazine.
Mesoridazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Mesoridazine.
Metaproterenol
Brexpiprazole may decrease the vasoconstricting activities of Orciprenaline.
Metaraminol
Brexpiprazole may decrease the vasoconstricting activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.
Methadone
The serum concentration of Brexpiprazole can be increased when it is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methadyl Acetate.
Methamphetamine
Brexpiprazole may decrease the stimulatory activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Brexpiprazole.
Methotrimeprazine
The serum concentration of Brexpiprazole can be increased when it is combined with Methotrimeprazine.
Methoxamine
Brexpiprazole may decrease the vasoconstricting activities of Methoxamine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.
Methyldopa
Brexpiprazole may decrease the vasoconstricting activities of Methyldopa.
METHYLDOPA ANHYDROUS
Brexpiprazole may decrease the vasoconstricting activities of Methyldopa.
Methylene blue
The metabolism of Brexpiprazole can be decreased when combined with Methylene blue.
METHYLEPHEDRINE, DL-
Brexpiprazole may decrease the vasoconstricting activities of DL-Methylephedrine.
Methylergonovine
Methylergometrine may increase the vasoconstricting activities of Brexpiprazole.
Methylphenidate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.
Metoprolol
The serum concentration of Brexpiprazole can be increased when it is combined with Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Melperone.
Metyrosine
The risk or severity of adverse effects can be increased when Metyrosine is combined with Brexpiprazole.
Mibefradil
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Mibefradil.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.
Midodrine
Brexpiprazole may decrease the vasoconstricting activities of Midodrine.
Midostaurin
The serum concentration of Brexpiprazole can be increased when it is combined with Midostaurin.
Mifepristone
The serum concentration of Brexpiprazole can be increased when it is combined with Mifepristone.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Brexpiprazole.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Brexpiprazole.
Milnacipran
The risk or severity of adverse effects can be increased when Milnacipran is combined with Brexpiprazole.
Minaprine
The metabolism of Brexpiprazole can be decreased when combined with Minaprine.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Mirabegron
The serum concentration of Brexpiprazole can be increased when it is combined with Mirabegron.
Mirtazapine
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Brexpiprazole can be decreased when it is combined with Mitotane.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Brexpiprazole.
Molindone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.
Moxonidine
Brexpiprazole may decrease the vasoconstricting activities of Moxonidine.
N-methylephedrine
Brexpiprazole may decrease the vasoconstricting activities of DL-Methylephedrine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Nadolol
Nadolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Brexpiprazole.
Naphazoline
Brexpiprazole may decrease the vasoconstricting activities of Naphazoline.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Brexpiprazole.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Brexpiprazole.
Nebivolol
Nebivolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Nefazodone
The serum concentration of Brexpiprazole can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir.
Netupitant
The serum concentration of Brexpiprazole can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Brexpiprazole can be decreased when it is combined with Nevirapine.
Nialamide
The metabolism of Brexpiprazole can be decreased when combined with Nialamide.
Nicardipine
The serum concentration of Brexpiprazole can be increased when it is combined with Nicardipine.
Nicergoline
Nicergoline may increase the antihypertensive activities of Brexpiprazole.
Nifedipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nifedipine.
Nilotinib
The serum concentration of Brexpiprazole can be increased when it is combined with Nilotinib.
Nilvadipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nilvadipine.
Nimesulide
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nimesulide.
Nimodipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nimodipine.
Nisoldipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nisoldipine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Brexpiprazole.
Nitrendipine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nitrendipine.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brexpiprazole.
Nordazepam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Nordazepam.
Norepinephrine
Brexpiprazole may decrease the vasoconstricting activities of Norepinephrine.
Norflurane
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Brexpiprazole.
Nylidrin
Brexpiprazole may decrease the vasoconstricting activities of Nylidrin.
Octylonium
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Otilonium.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole.
Olaparib
The serum concentration of Brexpiprazole can be increased when it is combined with Olaparib.
Olodaterol
Brexpiprazole may decrease the vasoconstricting activities of Olodaterol.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Brexpiprazole.
Ondansetron
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Opium.
Orphenadrine
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Brexpiprazole can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Brexpiprazole.
Oxprenolol
Oxprenolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Brexpiprazole.
Oxymetazoline
Brexpiprazole may decrease the vasoconstricting activities of Oxymetazoline.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Brexpiprazole.
p-Hydroxyamphetamine
Brexpiprazole may decrease the stimulatory activities of Hydroxyamphetamine.
Palbociclib
The serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib.
Paliperidone
Paliperidone may increase the antihypertensive activities of Brexpiprazole.
Panobinostat
The serum concentration of Brexpiprazole can be increased when it is combined with Panobinostat.
Paraldehyde
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.
Pargyline
The metabolism of Brexpiprazole can be decreased when combined with Pargyline.
Paroxetine
The serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Penbutolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.
Pentobarbital
The serum concentration of Brexpiprazole can be decreased when it is combined with Pentobarbital.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Brexpiprazole.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Perazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Perazine.
Pergolide
Brexpiprazole may decrease the vasoconstricting activities of Pergolide.
Periciazine
Propericiazine may increase the antihypertensive activities of Brexpiprazole.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Brexpiprazole.
Phendimetrazine
Brexpiprazole may decrease the vasoconstricting activities of Phendimetrazine.
Phenelzine
The metabolism of Brexpiprazole can be decreased when combined with Phenelzine.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Brexpiprazole.
Phenobarbital
The serum concentration of Brexpiprazole can be decreased when it is combined with Phenobarbital.
Phenoxybenzamine
Phenoxybenzamine may increase the antihypertensive activities of Brexpiprazole.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Phenoxyethanol.
Phentermine
Brexpiprazole may decrease the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Brexpiprazole may decrease the stimulatory activities of Phentermine.
Phentolamine
Phentolamine may increase the antihypertensive activities of Brexpiprazole.
Phentolamine Mesylate
Phentolamine may increase the antihypertensive activities of Brexpiprazole.
Phenylephrine
Brexpiprazole may decrease the vasoconstricting activities of Phenylephrine.
Phenylpropanolamine
Brexpiprazole may decrease the vasoconstricting activities of Phenylpropanolamine.
Phenytoin
The serum concentration of Brexpiprazole can be decreased when it is combined with Phenytoin.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Brexpiprazole.
Pinaverium
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Pinaverium.
Pindolol
Pindolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Brexpiprazole.
Pipamperone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Brexpiprazole.
Pirbuterol
Brexpiprazole may decrease the vasoconstricting activities of Pirbuterol.
Pirinitramide
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Pizotifen is combined with Brexpiprazole.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.
Posaconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Posaconazole.
Practolol
Practolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Pramipexole
Brexpiprazole may increase the sedative activities of Pramipexole.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Brexpiprazole.
Pramoxine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Prazepam.
Prazosin
Prazosin may increase the antihypertensive activities of Brexpiprazole.
Pregabalin
The therapeutic efficacy of Brexpiprazole can be increased when used in combination with Pregabalin.
Prenylamine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Prenylamine.
Prilocaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Prilocaine.
Primidone
The serum concentration of Brexpiprazole can be decreased when it is combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Procaine.
Procarbazine
The metabolism of Brexpiprazole can be decreased when combined with Procarbazine.
Procaterol
Brexpiprazole may decrease the vasoconstricting activities of Procaterol.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.
Promazine
The serum concentration of Brexpiprazole can be increased when it is combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Brexpiprazole.
Propafenone
Propafenone may increase the orthostatic hypotensive activities of Brexpiprazole.
Proparacaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Proparacaine.
Propiomazine
Propiomazine may increase the antihypertensive activities of Brexpiprazole.
Propiverine
Propiverine may increase the antihypertensive activities of Brexpiprazole.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.
Propoxyphene
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dextropropoxyphene.
Propranolol
Propranolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.
Pseudoephedrine
Brexpiprazole may decrease the stimulatory activities of Pseudoephedrine.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Brexpiprazole.
Quetiapine
Quetiapine may increase the antihypertensive activities of Brexpiprazole.
Quetiapine fumarate
Quetiapine may increase the antihypertensive activities of Brexpiprazole.
Quinagolide
The therapeutic efficacy of Quinagolide can be decreased when used in combination with Brexpiprazole.
Quinidine
The serum concentration of Brexpiprazole can be increased when it is combined with Quinidine.
Quinine
The serum concentration of Brexpiprazole can be increased when it is combined with Quinine.
Racepinephrine
Brexpiprazole may increase the antihypertensive activities of Racepinephrine.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Brexpiprazole.
Ranolazine
The serum concentration of Brexpiprazole can be increased when it is combined with Ranolazine.
Rasagiline
The metabolism of Brexpiprazole can be decreased when combined with Rasagiline.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Brexpiprazole.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Brexpiprazole.
Remoxipride
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Remoxipride.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Brexpiprazole.
Reproterol
Brexpiprazole may decrease the vasoconstricting activities of Reproterol.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Brexpiprazole.
Rifabutin
The serum concentration of Brexpiprazole can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Brexpiprazole can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Brexpiprazole can be decreased when it is combined with Rifapentine.
Rilmenidine
Brexpiprazole may decrease the vasoconstricting activities of Rilmenidine.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Brexpiprazole.
Ritodrine
Brexpiprazole may decrease the vasoconstricting activities of Ritodrine.
Ritonavir
The serum concentration of Brexpiprazole can be increased when it is combined with Ritonavir.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Brexpiprazole.
Rolapitant
The serum concentration of Brexpiprazole can be increased when it is combined with Rolapitant.
Ropinirole
The serum concentration of Brexpiprazole can be increased when it is combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ropivacaine.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Brexpiprazole.
Rotigotine
Brexpiprazole may increase the sedative activities of Rotigotine.
Rucaparib
The serum concentration of Brexpiprazole can be increased when it is combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Brexpiprazole.
Salmeterol
Brexpiprazole may decrease the vasoconstricting activities of Salmeterol.
Saquinavir
The serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Sarilumab.
Saxagliptin
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Brexpiprazole.
Saxagliptin Anhydrous
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Brexpiprazole.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Brexpiprazole.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Brexpiprazole.
Sertindole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sertindole.
Sertraline
The serum concentration of Brexpiprazole can be increased when it is combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Brexpiprazole.
Sildenafil
The serum concentration of Brexpiprazole can be increased when it is combined with Sildenafil.
Silodosin
Silodosin may increase the antihypertensive activities of Brexpiprazole.
Siltuximab
The serum concentration of Brexpiprazole can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Brexpiprazole can be increased when it is combined with Simeprevir.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Brexpiprazole.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Brexpiprazole.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Sotalol
Sotalol may increase the orthostatic hypotensive activities of Brexpiprazole.
ST. JOHN'S WORT EXTRACT
The serum concentration of Brexpiprazole can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.
Sulfisoxazole
The serum concentration of Brexpiprazole can be increased when it is combined with Sulfisoxazole.
Sulpiride
Brexpiprazole may increase the antipsychotic activities of Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Brexpiprazole.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Brexpiprazole.
Suvorexant
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Synephrine
Brexpiprazole may decrease the vasoconstricting activities of Synephrine.
Tadalafil
Tadalafil may increase the hypotensive activities of Brexpiprazole.
Talinolol
Talinolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Tamsulosin
Tamsulosin may increase the antihypertensive activities of Brexpiprazole.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Brexpiprazole.
Tedizolid
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Brexpiprazole.
Tedizolid Phosphate
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Brexpiprazole.
Telaprevir
The serum concentration of Brexpiprazole can be increased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Brexpiprazole can be increased when it is combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Brexpiprazole.
Terazosin
Terazosin may increase the antihypertensive activities of Brexpiprazole.
Terbinafine
The serum concentration of Brexpiprazole can be increased when it is combined with Terbinafine.
Terbutaline
Terbutaline may increase the orthostatic hypotensive activities of Brexpiprazole.
Terbutaline Sulfate
Terbutaline may increase the orthostatic hypotensive activities of Brexpiprazole.
Tertatolol
Tertatolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brexpiprazole.
Tetracaine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Tetrahydrozoline
Brexpiprazole may decrease the vasoconstricting activities of Tetryzoline.
Thalidomide
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
Theophylline may increase the hypotensive activities of Brexpiprazole.
Theophylline anhydrous
Theophylline may increase the hypotensive activities of Brexpiprazole.
Thiamylal
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Thiopental.
Thioproperazine
Thioproperazine may increase the antihypertensive activities of Brexpiprazole.
Thioridazine
The serum concentration of Brexpiprazole can be increased when it is combined with Thioridazine.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Brexpiprazole.
Tiapride
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tiapride.
Ticlopidine
The serum concentration of Brexpiprazole can be increased when it is combined with Ticlopidine.
Timolol
Timolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Timolol Anhydrous
Timolol may increase the orthostatic hypotensive activities of Brexpiprazole.
Tipranavir
The serum concentration of Brexpiprazole can be increased when it is combined with Tipranavir.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.
Tocilizumab
The serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Brexpiprazole.
Tolazoline
Tolazoline may increase the antihypertensive activities of Brexpiprazole.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Brexpiprazole.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Brexpiprazole.
Tolfenamic Acid
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Tolfenamic Acid.
Toloxatone
The metabolism of Brexpiprazole can be decreased when combined with Toloxatone.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Brexpiprazole.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Brexpiprazole.
Tranilast
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Tranilast.
Tranylcypromine
The serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Brexpiprazole.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Brexpiprazole.
Triazulenone
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Loprazolam.
Trifluoperazine
Trifluoperazine may increase the antihypertensive activities of Brexpiprazole.
Triflupromazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Triflupromazine.
Trimebutine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Trimebutine.
Trimethadione
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Trimethadione.
Trimipramine
Trimipramine may increase the antihypertensive activities of Brexpiprazole.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Brexpiprazole.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Brexpiprazole.
Tulobuterol
Brexpiprazole may decrease the vasoconstricting activities of Tulobuterol.
Urapidil
Urapidil may increase the antihypertensive activities of Brexpiprazole.
Urethane
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Valproic Acid.
Vardenafil
Vardenafil may increase the hypotensive activities of Brexpiprazole.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Brexpiprazole.
Venlafaxine
The serum concentration of Brexpiprazole can be increased when it is combined with Venlafaxine.
Verapamil
The serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Brexpiprazole.
Vilanterol
Brexpiprazole may decrease the vasoconstricting activities of Vilanterol.
Vilazodone
The risk or severity of adverse effects can be increased when Vilazodone is combined with Brexpiprazole.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Brexpiprazole.
Vinpocetine
The risk or severity of hypotension can be increased when Brexpiprazole is combined with Vinpocetine.
Voriconazole
The serum concentration of Brexpiprazole can be increased when it is combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Brexpiprazole.
Xamoterol
Brexpiprazole may decrease the vasoconstricting activities of Xamoterol.
Xylazine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Xylazine.
Xylometazoline
Brexpiprazole may decrease the vasoconstricting activities of Xylometazoline.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Brexpiprazole.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Brexpiprazole.
Ziprasidone
The serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Brexpiprazole.
Zolpidem
Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Brexpiprazole.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Brexpiprazole.
Zotepine
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Zotepine.
Zuclopenthixol
Zuclopenthixol may increase the antihypertensive activities of Brexpiprazole.
